drug · small molecule
ensifentrine
Marketedupdated 3mo agoby Verona Pharma Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 investigational indications.
targets
Phosphodiesterase 3Phosphodiesterase 4
all catalysts(0)
nothing on the calendar yet
Trials studying ensifentrine
- phase2A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
- phase2Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
- phase2A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
- phase2A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
- phase3A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- phase3Effect of Ensifentrine Treatment on CAT Score
- phase3A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
- phase3A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 26, 2029
~2.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Jun 25, 2044formulationUS 12251384
- Feb 20, 2043formulationUS 12409180
- Sep 15, 2035formulationUS 10945950
- Sep 15, 2035formulationUS 9956171
- Aug 21, 2031compositionUS 9062047
FDA exclusivities (1)
- Jun 26, 2029NCENew Chemical Entity (5y)2.9y
News(4)
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 6d ago
- A COPD drug from China draws $115M in venture fundingExpedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.biopharma_dive · 6d ago
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 7d ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that